Keyphrases
Patient-derived
100%
Pancreatic Cancer
100%
Tumor Regression
100%
Cancer Xenograft
100%
KRAS mutant
100%
Patient-derived Xenograft
50%
Tumor
50%
Immunodeficient Mice
50%
Pancreatic Ductal Adenocarcinoma
50%
Pancreatic Duct Cells
50%
Adenocarcinoma Cells
50%
ERK Pathway
25%
Fibrosis
25%
Further Development
25%
Cell Proliferation
25%
Unmet Medical Need
25%
Intraperitoneal Injection
25%
Daily Dose
25%
Anticancer Activity
25%
Proliferating Cells
25%
Target Engagement
25%
Residual Tumor
25%
Tissue Architecture
25%
Regress
25%
RAS Inhibition
25%
Phospho-ERK
25%
Toxin Activity
25%
Hard to Treat
25%
Cell Line-derived Xenograft
25%
Medicine and Dentistry
Xenograft
100%
Tumor Regression
100%
Pancreas Cancer
100%
Pancreas Adenocarcinoma
100%
Neoplasm
75%
Biological Product
50%
Cell Proliferation
50%
Adenocarcinoma Cell Line
50%
Cleft
25%
Fibrosis
25%
Antineoplastic Activity
25%
Intraperitoneal Drug Administration
25%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Pancreas Adenocarcinoma
100%
Tumor Regression
100%
Neoplasm
75%
Biological Product
50%
Intraperitoneal Injection
25%
Fibrosis
25%
Immunology and Microbiology
Xenograft
100%
Cell Proliferation
66%
Biological Product
66%
Adenocarcinoma Cell Line
66%
Antineoplastic Activity
33%